4DMT is a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution.
4DMT is harnessing the power of directed evolution to unlock the full potential of gene therapy for rare and large market diseases in lysosomal storage diseases, ophthalmology, neuromuscular diseases, and cystic fibrosis.
4DMT was founded in 2013 by David Kirn, David Schaffer, Theresa Janke and Melissa Kotterman. The company is headquartered in Emeryville, California.
4DMT’s proprietary Therapeutic Vector Evolution platform enables a “disease first” approach to product discovery and development, thereby empowering customization of AAV vectors to target specific tissue types associated with the underlying disease.
4DMT vectors are designed to exhibit improved therapeutic profiles that enable the company to pursue previously untreatable patient populations and to address a broad range of rare and large market disease markets.
4DMT is backed Arrowmark Partners, Pfizer Ventures, Berkeley Catalyst Fund, Viking Global Investors, Amzak Health, Casdin Capital, Cystic Fibrosis Foundation, Longevity Vision Fund, MiraeAsset Financial Group and others. The company raised $75M in Series C round on June 16, 2020. This brings 4DMT's total funding to $175M to date.